Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-2376 in advanced solid tumors with KRAS or EGFR mutations
NCT05163028Phase 1Active, not recruiting
- Sponsor
- HUYABIO International, LLC
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of GH21 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic cancer (PC), sponsored by HUYABIO International, LLC. Primary endpoints: Maximum Tolerated Dose at 36 months and Recommended Phase 2 Dose at 36 months. Started Dec 2021; status: active, not recruiting.
02
Drugs
GH21
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05163028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163028.